Safety and Tolerability of Fenfluramine in CDKL5 Deficiency Disorder

Safety and long-term tolerability remain central considerations in developmental and epileptic encephalopathies, particularly in patient populations that often require chronic multidrug treatment from an early age. In CDKL5 deficiency disorder (CDD), where patients frequently receive multiple antiseizure therapies concurrently, understanding the adverse event profile of emerging treatments is critical for clinicians and caregivers alike.

In this Special Report, Sam Amin, MD, discusses safety findings from a recent phase 3 randomized, double-blind, placebo-controlled study evaluating fenfluramine in patients with CDD. Amin, a study author with expertise in pediatric epileptic disorders, provides perspective on how the observed safety findings compare with the known profile of fenfluramine and what clinicians should consider when incorporating the therapy into practice.

In this episode, Amin reviews treatment-emergent adverse events observed during the trial, including somnolence and gastrointestinal events, while also highlighting the cardiovascular monitoring strategy used throughout the study. He additionally discusses the absence of valvular heart disease or pulmonary arterial hypertension among enrolled patients during the trial period.